IL74985A - Contrast agents for nmr imaging - Google Patents

Contrast agents for nmr imaging

Info

Publication number
IL74985A
IL74985A IL74985A IL7498585A IL74985A IL 74985 A IL74985 A IL 74985A IL 74985 A IL74985 A IL 74985A IL 7498585 A IL7498585 A IL 7498585A IL 74985 A IL74985 A IL 74985A
Authority
IL
Israel
Prior art keywords
vesicles
agent
particles
contrast agents
contrast enhancement
Prior art date
Application number
IL74985A
Other languages
English (en)
Other versions
IL74985A0 (en
Original Assignee
Vestar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vestar Inc filed Critical Vestar Inc
Publication of IL74985A0 publication Critical patent/IL74985A0/xx
Publication of IL74985A publication Critical patent/IL74985A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Engineering & Computer Science (AREA)
  • Signal Processing (AREA)
  • Immunology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Dispersion Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Gyroscopes (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
IL74985A 1984-04-27 1985-04-22 Contrast agents for nmr imaging IL74985A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60472184A 1984-04-27 1984-04-27
US06/720,954 US4728575A (en) 1984-04-27 1985-04-10 Contrast agents for NMR imaging

Publications (2)

Publication Number Publication Date
IL74985A0 IL74985A0 (en) 1985-08-30
IL74985A true IL74985A (en) 1989-03-31

Family

ID=27084736

Family Applications (1)

Application Number Title Priority Date Filing Date
IL74985A IL74985A (en) 1984-04-27 1985-04-22 Contrast agents for nmr imaging

Country Status (12)

Country Link
US (1) US4728575A (de)
EP (1) EP0160552B1 (de)
KR (1) KR920010391B1 (de)
AT (1) ATE61117T1 (de)
AU (1) AU585506B2 (de)
CA (1) CA1245553A (de)
DE (1) DE3581830D1 (de)
DK (1) DK168853B1 (de)
ES (1) ES8703019A1 (de)
HU (1) HU194741B (de)
IE (1) IE58354B1 (de)
IL (1) IL74985A (de)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US5017379A (en) * 1984-05-25 1991-05-21 Lemelson Jerome H Drug units and methods for treating blood clots
SE465907B (sv) * 1984-11-01 1991-11-18 Nyegaard & Co As Diagnosticeringsmedel innehaallande en paramagnetisk metall
DE3577185D1 (de) * 1984-11-01 1990-05-23 Nycomed As Paramagnetische kontrastmittel fuer die anwendung in "in vivo" nmr-diagnostischen methoden und die herstellung davon.
DE3508000A1 (de) * 1985-03-04 1986-09-04 Schering AG, Berlin und Bergkamen, 1000 Berlin Ferromagnetische partikel fuer die nmr-diagnostik
US5314642A (en) * 1984-11-27 1994-05-24 Igen, Inc. Interaction system comprising a surfactant-stabilized aqueous phase containing an antibody fragment
US4951675A (en) * 1986-07-03 1990-08-28 Advanced Magnetics, Incorporated Biodegradable superparamagnetic metal oxides as contrast agents for MR imaging
US4770183A (en) * 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US5219554A (en) 1986-07-03 1993-06-15 Advanced Magnetics, Inc. Hydrated biodegradable superparamagnetic metal oxides
IL79559A0 (en) * 1986-07-29 1986-10-31 Univ Ramot Contrast agents for nmr medical imaging
US5320906A (en) * 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
DE3865108D1 (de) * 1987-06-23 1991-10-31 Hafslund Nycomed Innovation Bilderzeugung mittels magnetischer resonanz.
US5681543A (en) * 1988-02-29 1997-10-28 Shering Aktiengesellschaft Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
DE68912139T2 (de) * 1988-11-09 1994-04-28 Colin Tilcock Liposomale radiologische kontrastmittel.
US5314681A (en) * 1988-12-23 1994-05-24 Nycomed Innovation Ab Composition of positive and negative contrast agents for electron spin resonance enhanced magnetic resonance imaging
AU639925B2 (en) * 1989-04-18 1993-08-12 Nexstar Pharmaceuticals, Inc. Liposomal targeting of ischemic tissue
US5230883A (en) * 1989-05-04 1993-07-27 Wisconsin Alumni Research Foundation Method for localization and treatment of tumors using polylysine complexes
US5087440A (en) * 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
US5064636A (en) * 1989-10-19 1991-11-12 Li King C P Paramagnetic oil emulsions as enteric MRI contrast agents
US5120527A (en) * 1989-10-19 1992-06-09 King Chuen Peter Li Paramagnetic oil emulsions as mri contrast agents
US5123414A (en) * 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5656211A (en) * 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5209720A (en) * 1989-12-22 1993-05-11 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US6146657A (en) * 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5773024A (en) * 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5776429A (en) * 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US20020150539A1 (en) * 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US5088499A (en) * 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US6001335A (en) * 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US5228446A (en) * 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5149319A (en) * 1990-09-11 1992-09-22 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids
US5922304A (en) * 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5305757A (en) * 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5230882A (en) * 1989-12-22 1993-07-27 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5525232A (en) * 1990-03-02 1996-06-11 The Liposome Company, Inc. Method for entrapment of cationic species in lemellar vesicles
US5215680A (en) * 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
GB9024528D0 (en) * 1990-11-12 1991-01-02 Instrumentarium Corp Improvements in and relating to magnetic resonance imaging
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5874062A (en) * 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5240693A (en) * 1991-05-01 1993-08-31 University Of New Mexico Image enhancement by coadministration of biomodulators and structurally modified imaging agents
WO1992019264A1 (en) * 1991-05-01 1992-11-12 University Of New Mexico Biomodulators as universal imaging agents
EP0594640A4 (en) * 1991-05-23 1998-06-03 Evan C Unger Liposoluble compounds for magnetic resonance imaging
US5443813A (en) * 1991-06-06 1995-08-22 Associated Universities, Inc. Loading and conjugating cavity biostructures
US5262532A (en) * 1991-07-22 1993-11-16 E.R. Squibb & Sons, Inc. Paramagnetic metalloporphyrins as contrast agents for magnetic resonance imaging
US5325860A (en) * 1991-11-08 1994-07-05 Mayo Foundation For Medical Education And Research Ultrasonic and interventional catheter and method
EP0804944A3 (de) 1992-05-04 1998-08-26 UNGER, Evan C Ein Verfahren zur Erzeugung einer Gaszusammensetzung in einem biologischen Gewebe oder Flüssigkeit in vivo
US5464696A (en) * 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
US5730130A (en) * 1993-02-12 1998-03-24 Johnson & Johnson Professional, Inc. Localization cap for fiducial markers
US5593688A (en) * 1993-06-25 1997-01-14 Nexstar Pharmaceuticals, Inc. Liposomal targeting of ischemic tissue
US6004534A (en) * 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
WO1995003035A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US5736121A (en) * 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
US5567410A (en) * 1994-06-24 1996-10-22 The General Hospital Corporation Composotions and methods for radiographic imaging
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5997898A (en) * 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6521211B1 (en) * 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6333971B2 (en) 1995-06-07 2001-12-25 George S. Allen Fiducial marker
US5833948A (en) * 1995-06-15 1998-11-10 Bracco Research S.A. Blood-pool imaging composition comprising micelles containing a lipophilic chelating agent and a non-ionic surfactant
CA2252617A1 (en) 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
ES2289188T3 (es) * 1996-09-11 2008-02-01 Bristol-Myers Squibb Medical Imaging, Inc. Procedimiento para la obtencion de imagenes para el diagnostico usando un agente de contraste y un vasodilatador.
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6537246B1 (en) * 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
AU7104598A (en) 1997-04-09 1998-10-30 Philipp Lang New technique to monitor drug delivery noninvasively (in vivo)
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US7452551B1 (en) 2000-10-30 2008-11-18 Imarx Therapeutics, Inc. Targeted compositions for diagnostic and therapeutic use
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6734171B1 (en) 1997-10-10 2004-05-11 Inex Pharmaceuticals Corp. Methods for encapsulating nucleic acids in lipid bilayers
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
ATE276745T1 (de) * 1998-04-09 2004-10-15 Amersham Health As Verwendung von teilchenförmigen kontrastmitteln in der diagnostischen bilderzeugung zur untersuchung physiologischer parameter
JP5074652B2 (ja) 2000-02-08 2012-11-14 ライスユニバーシティ 治療法および診断法において使用される光学活性なナノ粒子
US20030129223A1 (en) * 2000-10-11 2003-07-10 Targesome, Inc. Targeted multivalent macromolecules
US20030133972A1 (en) * 2000-10-11 2003-07-17 Targesome, Inc. Targeted multivalent macromolecules
US20030082103A1 (en) * 2000-10-11 2003-05-01 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
NZ529347A (en) 2001-04-04 2008-01-31 Nordic Vaccine Technology As Use of at least one sterol capable of interacting with a nucleic acid and at least saponin to form immunostimulating complexes ( IMSCO )
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
WO2003079149A2 (en) * 2002-03-11 2003-09-25 The University Of Vermont And State Agriculture College Blood clotting predictor
US20090060992A1 (en) * 2002-05-08 2009-03-05 University Of Central Florida Research Foundation, Inc., Preparation of magneto-vesicles with DOPE/DDAB layers
WO2004023981A2 (en) * 2002-09-11 2004-03-25 Duke University Methods and compositions for blood pool identification, drug distribution quantification and drug release verification
US7769423B2 (en) * 2002-09-11 2010-08-03 Duke University MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting
US20060147509A1 (en) * 2002-10-02 2006-07-06 Kirkby Nikolai S Composition for vaccination
US20080241262A1 (en) * 2004-03-29 2008-10-02 The University Of Houston System Nanoshells and Discrete Polymer-Coated Nanoshells, Methods For Making and Using Same
NZ553698A (en) * 2004-09-13 2010-07-30 Gilead Sciences Inc Delivering iron to an animal
JP2008519642A (ja) * 2004-11-12 2008-06-12 ケーピーイー リミテッド ナノ粒子を介した超音波治療および診断影像法
CA2680606C (en) 2006-03-29 2014-08-05 Wayne State University Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
WO2007120818A2 (en) * 2006-04-12 2007-10-25 Massachusetts Institute Of Technology Compositions and methods for inhibiting adhesions
CN101583346B (zh) 2006-04-28 2015-08-19 儿童医院医疗中心 用于穿膜药物递送系统的皂化蛋白c和相关蛋白及肽的促融合性质
US20080241065A1 (en) * 2007-03-27 2008-10-02 Benaron David A Systems and methods for the detection and analysis of in vivo circulating cells, entities, and nanobots
US20110130444A1 (en) * 2007-05-04 2011-06-02 Stefan Moisyadi Methods and compositions for targeted delivery of gene therapeutic vectors
DE102008005673A1 (de) * 2008-01-23 2009-08-20 Universität Augsburg Bläschen, sowie Verfahren zur Herstellung und Manipulation von Bläschen
ES2594102T3 (es) 2008-04-18 2016-12-15 Vaxinnate Corporation Mutantes por deleción de la flagelina y métodos para su uso
US20090298103A1 (en) * 2008-05-20 2009-12-03 The University Of Vermont And State Agriculture College Predicting hemostatic risk; dependence on plasma composition
US8797031B2 (en) * 2011-01-27 2014-08-05 Siemens Medical Solutions Usa, Inc. MR imaging system for discriminating between imaged tissue types
EP2741784B1 (de) 2011-03-02 2017-05-17 Board Of Regents, The University Of Texas System Tusc2 therapien
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
US10736880B2 (en) 2015-12-18 2020-08-11 The Board Of Regents Of The University Of Texas Systems Therapeutics for preterm labor management
MX386249B (es) 2016-10-12 2025-03-18 Univ Texas Terapia tusc2 para usarse en el tratamiento de cáncer.
WO2019084661A1 (en) 2017-11-04 2019-05-09 Sona Nanotech Metal nanoparticles and methods of making same
CN111479557A (zh) 2017-12-15 2020-07-31 得克萨斯州大学系统董事会 用于使用外排体相关基因编辑来治疗癌症的方法和组合物
EP4005562A1 (de) 2018-03-23 2022-06-01 Bexion Pharmaceuticals, Inc. Pharmazeutische zusammensetzungen von saposin c und deren verwendung zur behandlung von krebs
KR20200136977A (ko) 2018-03-28 2020-12-08 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 엑소좀으로부터 단리된 dna에서의 후성유전학적 변화의 식별
EP3870700A1 (de) 2018-10-24 2021-09-01 Codiak BioSciences, Inc. Verfahren zur verbesserung der potenz der elektroporation
WO2020163705A1 (en) 2019-02-08 2020-08-13 Board Of Regents, The University Of Texas System Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction
KR20230005244A (ko) 2020-04-20 2023-01-09 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 생물학적 활성 건조 분말 조성물 및 이의 제조 및 사용 방법
US20230302154A1 (en) 2020-08-19 2023-09-28 The Board Of Regents Of The University Of Texas System Nanodrugs for targeted drug delivery and use thereof
EP4277933A4 (de) 2021-01-14 2024-12-11 Senti Biosciences, Inc. Sekretierbare nutzlastregulierung
AU2023271853A1 (en) 2022-05-18 2024-12-05 The Children's Hospital Of Philadelphia Compositions and methods for inducible alternative splicing regulation of gene expression

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3850578A (en) * 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US4320121A (en) * 1976-10-12 1982-03-16 Sears Barry D Method of emulsifying cholesterol, cholesterol esters and triglyceride compounds
US4192859A (en) * 1978-09-29 1980-03-11 E. R. Squibb & Sons, Inc. Contrast media containing liposomes as carriers
US4342739A (en) * 1979-01-09 1982-08-03 Fuji Photo Film Co., Ltd. Novel material for immunological assay of biochemical components and a process for the determination of said components
US4301054A (en) * 1979-06-04 1981-11-17 Thermal Imagery, Inc. Thermographic cholesteric coating compositions
GR77320B (de) * 1980-12-22 1984-09-11 Procter & Gamble
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3129906C3 (de) * 1981-07-24 1996-12-19 Schering Ag Paramagnetische Komplexsalze, deren Herstellung und Mittel zur Verwendung bei der NMR-Diagnostik
US4442834A (en) * 1981-10-02 1984-04-17 Jobst Institute, Inc. Pneumatic splint
DE3141641A1 (de) * 1981-10-16 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Ultraschall-kontrastmittel und dessen herstellung
US4452747A (en) * 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
NL194579C (nl) * 1983-01-21 2002-08-05 Schering Ag Diagnostisch middel.
FR2550449B1 (fr) * 1983-08-12 1986-01-31 Commissariat Energie Atomique Agents de relaxation specifiques d'organes ou de pathologies, utilisables pour modifier les contrastes en imagerie medicale par resonance magnetique nucleaire
CA1243602A (en) * 1983-08-25 1988-10-25 Hong-Ning Yeung Methods for enhancing the contrast in nmr imaging

Also Published As

Publication number Publication date
DE3581830D1 (de) 1991-04-04
KR850007562A (ko) 1985-12-07
EP0160552A3 (en) 1986-08-20
DK168853B1 (da) 1994-06-27
DK188785A (da) 1985-10-28
ATE61117T1 (de) 1991-03-15
ES542604A0 (es) 1987-01-16
US4728575A (en) 1988-03-01
AU4170385A (en) 1985-10-31
DK188785D0 (da) 1985-04-26
EP0160552A2 (de) 1985-11-06
CA1245553A (en) 1988-11-29
HU194741B (en) 1988-03-28
ES8703019A1 (es) 1987-01-16
IL74985A0 (en) 1985-08-30
IE58354B1 (en) 1993-09-08
HUT37569A (en) 1986-01-23
KR920010391B1 (ko) 1992-11-27
AU585506B2 (en) 1989-06-22
IE851035L (en) 1985-10-27
EP0160552B1 (de) 1991-02-27

Similar Documents

Publication Publication Date Title
AU585506B2 (en) Contrast agents for nmr imaging
Floren et al. Uptake of Lp (a) lipoprotein by cultured fibroblasts
Mauk et al. Vesicle targeting: timed release and specificity for leukocytes in mice by subcutaneous injection
EP0314262A3 (en) Mri system with open access to patient image volume
MX205459A (es) Agentes de contraste para resonancia magnetica nuclear y proceso para su preparacion
NO172729C (no) Fremgangsmaate for fremstilling av en suspensjon av fosfolipidvesikler.
NZ214228A (en) Agents for in vivo diagnostic use containing magnetic particles
IL68344A0 (en) Method to eliminate the effects of magnetic field inhomogeneities in nmr imaging
NL970040I2 (nl) Dipyridoxylfosfaten als contrastmiddelen bij de beeldvorming door kernmagnetische resonantie.
JPS5681868A (en) Magnet roll developing device
GB2177199A (en) Magnetic micro-particles as contrast agents in nuclear magnetic resonance imaging
DK0470188T3 (da) Hidtil ukendte magnetiske resonans-imaging-midler
ES8201799A1 (es) Un transductor electroacustico
JPS6490439A (en) Silver halide photographic sensitive material
GB2164155B (en) Flow imaging by means of nuclear magnetic resonance
汪承灏 et al. Generalized Green’s functions of surface excitation of elastic wave fields in a piezoelectric half-space
Le Grimellec et al. Effect of meleate on membrane physical state of brush border and basolateral membranes of the dog kidney
GB2083290A (en) Low-loss reactor
Anghileri et al. 67Ga and 59Fe uptake by tumor cells treated with hyperthermia or hyperthermia plus lanthanum
袁春波 et al. Effects of metal ions on the conformation of polar headgroup of sphingomyelin bilayer
DE3367850D1 (en) Lipid metabolism improving agents
SOKOLOVSKII Eddy current losses induced by rotation of magnetisation
JPS5574216A (en) Isolator
MARAGHECHI Excitation of electron plasma waves[Ph. D. Thesis]
Brady In vivo quantitation of the phosphorus-containing metabolites in rat hind limb by nuclear magnetic resonance spectroscopy during four weeks of creatine depletion induced by feeding beta-guanidinopropionic acid.

Legal Events

Date Code Title Description
HE Change of address of proprietor(s)
KB Patent renewed
KB Patent renewed
EXP Patent expired